| ICG group (n = 73) | Non-ICG group (n = 114) | p-value |
---|---|---|---|
Sex, n (%) | Â | Â | 0.524 |
  Male | 46 (63%) | 77 (67.5%) |  |
  Female | 27 (37%) | 37 (32.5%) |  |
Age, yearsa | 67 (57, 72) | 68 (59, 73) | 0.517 |
BMIa | 22.7 (20.7, 25.1) | 22.2 (19.9, 24.8) | 0.371 |
Comorbidities, n (%) | |||
  Hypertension | 22 (30.1%) | 36 (31.6%) | 0.835 |
  Diabetes | 18 (24.6%) | 17 (14.9%) | 0.096 |
  Cardiac dysfunction | 9 (12.3%) | 15 (13.2%) | 0.868 |
  Pulmonary dysfunction | 9 (12.3%) | 10 (8.8%) | 0.432 |
Preoperative therapy, n (%) | Â | Â | 0.010 |
  Chemoradiotherapy | 8 (10.9%) | 3 (2.6%) |  |
  Chemotherapy | 5 (6.9%) | 2 (1.8%) |  |
Tumor size, mma | 30 (20, 50) | 35 (20, 50) | 0.160 |
Tumor location, n (%) | Â | Â | 0.478 |
  Upper rectum | 35 (47.9%) | 47 (41.2%) |  |
  Middle rectum | 8 (11%) | 19 (16.7%) |  |
  Low rectum | 30 (41.1%) | 48 (42.1%) |  |
Tumor staging, n (%) | |||
  Stage I | 21 (28.7%) | 33 (28.9%) |  |
  Stage II | 18 (24.6%) | 27 (23.7%) |  |
  Stage III | 25 (34.2%) | 40 (35.1%) |  |
  Stage IV | 9 (12.5%) | 14 (12.3%) |  |